SEC Form SC 13G filed by Fractyl Health Inc.

SEC Form SC 13G filed by Fractyl Health Inc.

SEC Form SC 13G filed by Fractyl Health Inc.

SEC Form SC 13G filed by Fractyl Health Inc.

Recent Analyst Ratings for
$GUTS

Recent Analyst Ratings for
$GUTS

$GUTS
SEC Filings

$GUTS
Press Releases

$GUTS
Insider Trading

$GUTS
Analyst Ratings

$GUTS
Insider Purchases

$GUTS
Leadership Updates

$GUTS
Financials

$GUTS
Large Ownership Changes

Crush Q3 2025 with the Best AI Superconnector

Crush Q3 2025 with the Best AI Superconnector

SEC Form SCHEDULE 13G filed by Fractyl Health Inc.

Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 424B5 filed by Fractyl Health Inc.

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

SEC Form 4 filed by Director Thompson Christopher Charles

SEC Form 3 filed by new insider Thompson Christopher Charles

SEC Form 4 filed by Director Sheffield Ian

H.C. Wainwright initiated coverage on Fractyl Health with a new price target

Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

Evercore ISI initiated coverage on Fractyl Health

Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

Director Schulman Amy W bought $9,964 worth of shares (8,550 units at $1.17) (SEC Form 4)

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

11/13/24 5:17:27 PM ET

$GUTS

Medical/Dental Instruments

Health Care

Get the next $GUTS alert in real time by email

SC 13G 1 d863183dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

13d-2 (b)

(Amendment No. )

Fractyl Health, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

35168W103

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 35168W103				13G

(1)

All such shares are held of record by Mithril I (as defined in Item 2(a) below). Mithril GP (as defined in Item 2(a) below) is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities.

(2)

Based on 47,927,214 shares of the Issuer’s common stock (“Common Stock”) outstanding as of August 2, 2024 as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the United States Securities and Exchange Commission (the “Commission”) on August 14, 2024 (the “Form 10-Q”).


CUSIP No. 35168W103				13G

(1)

All such shares are held of record by Mithril I. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities.

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

All such shares are held of record by Mithril II (as defined in Item 2(a) below). Mithril II UGP (as defined in Item 2(a) below) is the general partner of Mithril II GP (as defined in Item 2(a) below), which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares.

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

All such shares are held of record by Mithril II. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares.

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

Includes (i) 5,160,301 shares held by Mithril I and (ii) 1,251,900 shares held by Mithril II. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril I. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril II. Ajay Royan is the authorized person of Mithril I GP and is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP and the members of the investment committee established by Mithril II GP. Each of the investment committees makes all investment decisions with respect to the shares held by each of Mithril I and Mithril II, respectively, and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Mithril I and Mithril II.

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.

Introductory Note: This joint statement on Schedule 13G (this “Statement”) is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value $0.00001 per share, of Fractyl Health, Inc. (the “Issuer”).

Item 1(a).

Name of Issuer:

Fractyl Health, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

3 Van de Graaff Drive, Suite 200

Burlington, MA 01803

Item 2(a).

Name of Person Filing:

This Statement is being filed by Mithril LP (“Mithril I”), Mithril GP LP (“Mithril GP”) Mithril II LP (“Mithril II”), Mithril II GP LP (“Mithril II GP”), Mithril II UGP LLC (“Mithril II UGP”, and together with Mithril I, Mithril GP, Mithril II and Mithril II GP LP, the “Reporting Entities”), Ajay Royan (“Royan”) and Peter Thiel (“Thiel”, and together with Royan, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons”.

Item 2(b)

Address of Principal Business Office, or if None, Residence:

The address of the principal business office of each Reporting Entity and the business address of each Reporting Individual is c/o Mithril Capital Management LLC, 111 Congress Ave., Suite 500, Austin, TX 78701.

Item 2(c).

Citizenship:

Mithril II UGP is a limited liability company organized under the laws of the State of Delaware. Each of Mithril I, Mithril GP, Mithril II and Mithril II GP is a limited partnership organized under the laws of the State of Delaware. Royan is a citizen of Canada. Thiel is a citizen of the United States of America.

Item 2(d).

Title of Class of Securities:

Common Stock, $0.00001 par value per share.

Item 2(e).

CUSIP Number:

35168W103

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

See Row 9 of the cover page for each Reporting Person.*

(b)

Percent of class:

See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote

See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

(ii)

Shared power to vote or to direct the vote

See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

(iii)

Sole power to dispose or to direct the disposition of

See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

(iv)

Shared power to dispose or to direct the disposition of

See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

*	Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Under certain circumstances set forth in the limited partnership agreements of each of Mithril I, Mithril GP, Mithril II and Mithril II GP and the limited liability company agreement of Mithril II UGP, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of the Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1 – Joint Filing Agreement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

November 13, 2024


Mithril LP

By:		Mithril GP LP
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan, Authorized Person

Mithril GP LP

By:		/s/ Ajay Royan
		Ajay Royan, Authorized Person

Mithril II LP

By:		Mithril II GP LP
Its:		General Partner
By:		Mithril II UGP LLC
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan, Managing Member

Mithril II GP LP

By:		Mithril II UGP LLC
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan Managing Member

Mithril II UGP LLC

By:		/s/ Ajay Royan
		Ajay Royan, Managing Member

		/s/ Ajay Royan
		Ajay Royan

		/s/ Peter Thiel
		Peter Thiel

Get the next $GUTS alert in real time by email

Date

Price Target

Rating

Analyst

9/15/2025

$9.00

Buy

H.C. Wainwright

8/28/2025

$3.60

Buy

Ladenburg Thalmann

2/28/2024

Outperform

Evercore ISI

2/27/2024

$18.00

Overweight

Morgan Stanley

2/27/2024

$26.00

Buy

BofA Securities

11/13/24 5:17:27 PM ET

$GUTS

Medical/Dental Instruments

Health Care

Get the next $GUTS alert in real time by email

SC 13G 1 d863183dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

13d-2 (b)

(Amendment No. )

Fractyl Health, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

35168W103

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)


CUSIP No. 35168W103				13G

(1)

(2)


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.


CUSIP No. 35168W103				13G

(1)

(2)	Based on 47,927,214 shares of Common Stock outstanding as of August 2, 2024, as set forth in the Form 10-Q.

Item 1(a).

Name of Issuer:

Fractyl Health, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

3 Van de Graaff Drive, Suite 200

Burlington, MA 01803

Item 2(a).

Name of Person Filing:

Item 2(b)

Address of Principal Business Office, or if None, Residence:

Item 2(c).

Citizenship:

Item 2(d).

Title of Class of Securities:

Common Stock, $0.00001 par value per share.

Item 2(e).

CUSIP Number:

35168W103

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

See Row 9 of the cover page for each Reporting Person.*

(b)

Percent of class:

See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote

See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

(ii)

Shared power to vote or to direct the vote

See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

(iii)

Sole power to dispose or to direct the disposition of

See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

(iv)

Shared power to dispose or to direct the disposition of

See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

*	Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of the Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

Material to be Filed as Exhibits.

Exhibit 1 – Joint Filing Agreement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

November 13, 2024


Mithril LP

By:		Mithril GP LP
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan, Authorized Person

Mithril GP LP

By:		/s/ Ajay Royan
		Ajay Royan, Authorized Person

Mithril II LP

By:		Mithril II GP LP
Its:		General Partner
By:		Mithril II UGP LLC
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan, Managing Member

Mithril II GP LP

By:		Mithril II UGP LLC
Its:		General Partner

By:		/s/ Ajay Royan
		Ajay Royan Managing Member

Mithril II UGP LLC

By:		/s/ Ajay Royan
		Ajay Royan, Managing Member

		/s/ Ajay Royan
		Ajay Royan

		/s/ Peter Thiel
		Peter Thiel

Get the next $GUTS alert in real time by email

Date

Price Target

Rating

Analyst

9/15/2025

$9.00

Buy

H.C. Wainwright

8/28/2025

$3.60

Buy

Ladenburg Thalmann

2/28/2024

Outperform

Evercore ISI

2/27/2024

$18.00

Overweight

Morgan Stanley

2/27/2024

$26.00

Buy

BofA Securities

Name of Reporting Persons

Mithril LP

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐ (b) ☒

SEC Use Only

Citizenship or Place of Organization

Delaware